|
Introduction
Our platform fully complies with the medical regulations (Good Tissue Practice, GTP) in Taiwan. We have four clinical trials are ongoing by now including GXHPC1, GXNPC1, GXCPC1 and GXIPC1, which the indications are liver cirrhosis, chronic stroke, osteoarthritis and diabetes, respectively.
More Information
|